MDxHealth: promising results from prostate cancer study.

(CercleFinance.com) - Belgium's MDxHealth has announced promising results from a study of an urine-based, molecular diagnostic test to assess a man's risk for prostate cancer.


The study showed that SelectMDx liquid biopsy test identified men at risk for clinically significant prostate cancer who would benefit from a multiparametric MRI (mpMRI) scan.

According to the healthcare company, SelectMDx may hence aid in the reduction of unnecessary invasive biopsies and the expense associated with mpMRI.

MRI scans are particularly expensive in the US, with insurance companies and patients paying up to 3,000 dollars, depending on the medical facility.

Copyright (c) 2017 CercleFinance.com. All rights reserved.